At Aderis, strong strategic alliances are an integral part of our corporate strategy. We seek to in-license technologies that support our existing cardiovascular and CNS programs in order to maintain a broad product portfolio. To remain focused on our product development strengths, we also seek to out-license products aimed at large and/or international markets. By capitalizing on our own strengths and those of our partners, Aderis is able to maximize value for all parties while speeding time to market for our product candidates.

Rotigotine (all indications) Binodenoson Selodenoson-IV     Selodenoson-SR     MRE-0094 CF101 Canfite Canfite1

Aderis has established development and sales partnerships with dominant players in the pharmaceutical industry.
For details about our existing partnerships please click on each partner's logo.

For more information about partnering opportunities with Aderis, click here.

¹ Selected European countries including: France, Germany, Italy & U.K.